Top

Published in:

01-07-2015 | Review Paper

Pericytes in sarcomas of bone

Authors: Le Chang, Vi Nguyen, Alan Nguyen, Michelle A. Scott, Aaron W. James

Published in: Medical Oncology | Issue 7/2015

Abstract

Pericytes are mesenchymal cells that closely enwrap small blood vessels, lying in intimate association with the endothelium. Pericytes have recently gained attention as an important mediator of vascular biology and angiogenesis in cancer. Although better studied in carcinoma, pericytes have known interaction with sarcomas of bone, including Ewing’s sarcoma, osteosarcoma, and chondrosarcoma. Best studied is Ewing’s sarcoma (ES), which displays a prominent perivascular growth pattern. Signaling pathways of known importance in intratumoral pericytes in ES include Notch, PDGF/PDGFR-β, and VEGF signaling. In summary, pericytes serve important functions in the tumor microenvironment. Improved understanding of pericyte biology may hold significant implications for the development of new therapies in sarcoma.

Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671–4.PubMedCrossRef

Betsholtz C, Lindblom P, Gerhardt H. Role of pericytes in vascular morphogenesis. EXS. 2005;94:115–25.PubMed

Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–10.PubMedCrossRef

Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97(6):512–23.PubMedCrossRef

Hirschi KK, D’Amore PA. Pericytes in the microvasculature. Cardiovasc Res. 1996;32(4):687–98.PubMedCrossRef

Stark K, et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct’ them with pattern-recognition and motility programs. Nat Immunol. 2013;14(1):41–51.PubMedCrossRef

Schönfelder U, et al. In situ observation of living pericytes in rat retinal capillaries. Microvasc Res. 1998;56(1):22–9.PubMedCrossRef

Lindahl P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277(5323):242–5.PubMedCrossRef

Hellström M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153(3):543–53.PubMedCentralPubMedCrossRef

10.

Abramsson A, et al. Analysis of mural cell recruitment to tumor vessels. Circulation. 2002;105(1):112–7.PubMedCrossRef

11.

Cooke VG, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012;21(1):66–81.PubMedCentralPubMedCrossRef

12.

Xian X, et al. Pericytes limit tumor cell metastasis. J Clin Invest. 2006;116(3):642–51.PubMedCentralPubMedCrossRef

13.

Lindblom P, et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003;17(15):1835–40.PubMedCentralPubMedCrossRef

14.

Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–87.PubMedCrossRef

15.

Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193–215.PubMedCrossRef

16.

Shih SC, et al. Transforming growth factor beta1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyte-induced vascular survival in vivo. Proc Natl Acad Sci USA. 2003;100(26):15859–64.PubMedCentralPubMedCrossRef

17.

Ozerdem U, et al. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn. 2001;222(2):218–27.PubMedCrossRef

18.

Greenhalgh SN, Iredale JP, Henderson NC, Origins of fibrosis: pericytes take centre stage. F1000Prime Rep. 2013;5:37.

19.

Schrimpf C, Duffield JS. Mechanisms of fibrosis: the role of the pericyte. Curr Opin Nephrol Hypertens. 2011;20(3):297–305.PubMedCrossRef

20.

Dulmovits BM, Herman IM. Microvascular remodeling and wound healing: a role for pericytes. Int J Biochem Cell Biol. 2012;44(11):1800–12.PubMedCentralPubMedCrossRef

21.

Quaegebeur A, Segura I, Carmeliet P. Pericytes: blood-brain barrier safeguards against neurodegeneration? Neuron. 2010;68(3):321–3.PubMedCrossRef

22.

Farrington-Rock C, et al. Chondrogenic and adipogenic potential of microvascular pericytes. Circulation. 2004;110(15):2226–32.PubMedCrossRef

23.

Paquet-Fifield S, et al. A role for pericytes as microenvironmental regulators of human skin tissue regeneration. J Clin Invest. 2009;119(9):2795–806.PubMedCentralPubMed

24.

Murray IR, et al. Natural history of mesenchymal stem cells, from vessel walls to culture vessels. Cell Mol Life Sci. 2014;71(8):1353–74.PubMedCrossRef

25.

Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med (Berl). 2008;86(2):135–44.CrossRef

26.

Morikawa S, et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002;160(3):985–1000.PubMedCentralPubMedCrossRef

27.

Cao Y, et al. Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer. 2013;119(2):313–24.PubMedCrossRef

28.

Xu L, et al. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 2005;65(13):5711–9.PubMedCrossRef

29.

Paulsson J, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol. 2009;175(1):334–41.PubMedCentralPubMedCrossRef

30.

Kitadai Y, et al. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer. 2006;119(11):2567–74.PubMedCrossRef

31.

Wang W, et al. Effect of platelet-derived growth factor-B on renal cell carcinoma growth and progression. Urol Oncol. 2015;33(4):168.e17–27.

32.

Minami Y, et al. Prostaglandin I2 analog suppresses lung metastasis by recruiting pericytes in tumor angiogenesis. Int J Oncol. 2015;46(2):548–54.PubMed

33.

Delattre O, et al. The Ewing family of tumors–a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994;331(5):294–9.PubMedCrossRef

34.

Downing JR, et al. Detection of the (11;22)(q24;q12) translocation of Ewing’s sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. Am J Pathol. 1993;143(5):1294–300.PubMedCentralPubMed

35.

Maheshwari AV, Cheng EY. Ewing sarcoma family of tumors. J Am Acad Orthop Surg. 2010;18(2):94–107.PubMed

36.

Subbiah V, et al. Ewing’s sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009;10(1–2):126–40.PubMedCrossRef

37.

Yu L, et al. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing’s sarcomas. Cancer Res. 2010;70(4):1334–43.PubMedCentralPubMedCrossRef

38.

Reddy K, et al. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing’s tumor vessels. Mol Cancer Res. 2008;6(6):929–36.PubMedCentralPubMedCrossRef

39.

Zhou Z, et al. Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing’s sarcoma in the lung. Angiogenesis. 2011;14(2):125–33.PubMedCentralPubMedCrossRef

40.

Gridley T. Notch signaling in the vasculature. Curr Top Dev Biol. 2010;92:277–309.PubMedCentralPubMedCrossRef

41.

Roca C, Adams RH. Regulation of vascular morphogenesis by Notch signaling. Genes Dev. 2007;21(20):2511–24.PubMedCrossRef

42.

Shawber CJ, Kitajewski J. Notch function in the vasculature: insights from zebrafish, mouse and man. BioEssays. 2004;26(3):225–34.PubMedCrossRef

43.

Thomas JL, et al. Interactions between VEGFR and Notch signaling pathways in endothelial and neural cells. Cell Mol Life Sci. 2013;70(10):1779–92.PubMedCentralPubMedCrossRef

44.

Villa N, et al. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev. 2001;108(1–2):161–4.PubMedCrossRef

45.

Liu H, Kennard S, Lilly B. NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. Circ Res. 2009;104(4):466–75.PubMedCentralPubMedCrossRef

46.

Kofler NM, et al. Notch signaling in developmental and tumor angiogenesis. Genes Cancer. 2011;2(12):1106–16.PubMedCentralPubMedCrossRef

47.

Zhou Z, Yu L, Kleinerman ES. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. Cancer. 2014;120(4):579–88.PubMedCentralPubMedCrossRef

48.

Stewart KS, et al. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood. 2011;117(2):719–26.PubMedCentralPubMedCrossRef

49.

Schadler KL, et al. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing’s sarcoma. Clin Cancer Res. 2010;16(3):848–56.PubMedCentralPubMedCrossRef

50.

Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene. 2008;27(38):5132–7.PubMedCentralPubMedCrossRef

51.

Rehman AO, Wang CY. Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol. 2006;16(6):293–300.PubMedCrossRef

52.

Lindahl P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277(5323):242–5.PubMedCrossRef

53.

Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005;7(4):452–64.PubMedCentralPubMedCrossRef

54.

Uren A, et al. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing’s sarcoma cells. Oncogene. 2003;22(15):2334–42.PubMedCrossRef

55.

Wang YX, et al. Inhibiting platelet-derived growth factor beta reduces Ewing’s sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo. 2009;23(6):903–9.PubMed

56.

González I, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res. 2004;10(2):751–61.PubMedCrossRef

57.

Merchant MS, et al. Potential use of imatinib in Ewing’s Sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst. 2002;94(22):1673–9.PubMedCrossRef

58.

Bond M, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;50(2):254–8.PubMedCrossRef

59.

Chao J, et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 2010;30(2):547–52.PubMed

60.

Chugh R, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27(19):3148–53.PubMedCrossRef

61.

Dubois SG, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children’s oncology group study. Clin Cancer Res. 2011;17(15):5113–22.PubMedCentralPubMedCrossRef

62.

Wang Y, et al. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer. 2010;116(16):3892–902.PubMedCrossRef

63.

Reddy K, et al. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing’s sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer. 2008;123(4):831–7.PubMedCentralPubMedCrossRef

64.

Hamdan R, Zhou Z, Kleinerman ES. Blocking SDF-1alpha/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. Mol Cancer Ther. 2014;13(2):483–91.PubMedCentralPubMedCrossRef

65.

Hagedorn M, et al. VEGF coordinates interaction of pericytes and endothelial cells during vasculogenesis and experimental angiogenesis. Dev Dyn. 2004;230(1):23–33.PubMedCrossRef

66.

Reddy K, et al. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature. Angiogenesis. 2008;11(3):257–67.PubMedCentralPubMedCrossRef

67.

Lee TH, et al. Production of VEGF165 by Ewing’s sarcoma cells induces vasculogenesis and the incorporation of CD34 + stem cells into the expanding tumor vasculature. Int J Cancer. 2006;119(4):839–46.PubMedCrossRef

68.

Zhou Z, et al. Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res. 2007;13(16):4867–73.PubMedCrossRef

69.

Greenberg JI, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456(7223):809–13.PubMedCentralPubMedCrossRef

70.

Glade Bender JL, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2008;26(3):399–405.PubMedCrossRef

71.

Widemann BC, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children’s Oncology Group Phase I Consortium report. Clin Cancer Res. 2012;18(21):6011–22.PubMedCentralPubMedCrossRef

72.

Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.PubMedCrossRef

73.

Rytting M, et al. Osteosarcoma in preadolescent patients. Clin Orthop Relat Res. 2000;373:39–50.PubMedCrossRef

74.

Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19(3):292–315.PubMedCrossRef

75.

Fletcher CDM, et al. World health organization classifications of tumours of soft tissue and bone. Lyon: International Agency for Research on Cancer; 2013.

76.

Leddy LR, Holmes RE. Chondrosarcoma of bone. Cancer Treat Res. 2014;162:117–30.PubMedCrossRef

77.

Hemingway F, et al. Smooth muscle actin expression in primary bone tumours. Virchows Arch. 2012;460(5):525–34.PubMedCrossRef

78.

McGary EC, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res. 2002;8(11):3584–91.PubMed

79.

Kalinski T, et al. Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors. Pathol Res Pract. 2009;205(5):339–45.PubMedCrossRef

80.

Engin F, et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet. 2009;18(8):1464–70.PubMedCentralPubMedCrossRef

81.

Zhang P, et al. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene. 2010;29(20):2916–26.PubMedCentralPubMedCrossRef

82.

Hughes DP. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res. 2009;152:479–96.PubMedCrossRef

83.

Tanaka M, et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer. 2009;100(12):1957–65.PubMedCentralPubMedCrossRef

84.

Kuzmanov A, et al. Overexpression of factor inhibiting HIF-1 enhances vessel maturation and tumor growth via platelet-derived growth factor-C. Int J Cancer. 2012;131(5):E603–13.PubMedCrossRef

85.

Niu F, et al. Identification and functional analysis of differentially expressed genes related to metastatic osteosarcoma. Asian Pac J Cancer Prev. 2014;15(24):10797–801.PubMedCrossRef

86.

Maniscalco L, et al. PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology. Vet J. 2013;195(1):41–7.PubMedCrossRef

87.

Franchi A, et al. Dedifferentiated peripheral chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of four cases. Virchows Arch. 2012;460(3):335–42.PubMedCrossRef

88.

Sulzbacher I, et al. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol. 2001;25(12):1520–7.PubMedCrossRef

Title: Pericytes in sarcomas of bone
Authors: Le Chang
Vi Nguyen
Alan Nguyen
Michelle A. Scott
Aaron W. James
Publication date: 01-07-2015
Publisher: Springer US
Published in: Medical Oncology / Issue 7/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-015-0651-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2015

Antithymocyte globulin combined with cyclosporine A down-regulates T helper 1 cells by modulating T cell immune response cDNA 7 in aplastic anemia

Lymphatic-targeted therapy following neoadjuvant chemotherapy: a promising strategy for lymph node-positive breast cancer treatment

Erratum to: Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells

Dysregulated expression of Dicer in invasive ductal breast carcinoma

Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for chronic lymphocytic leukemia

Crizotinib-loaded polymeric nanoparticles in lung cancer chemotherapy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage